S-1: Akari Therapeutics Faces Going Concern Doubts Amid ADC Focus

Akari Therapeutics, an oncology company, is shifting its focus to next-generation antibody-drug conjugates (ADCs) following a recent merger, but faces significant financial challenges and a Nasdaq delisting threat.

Summary

• Akari Therapeutics has transitioned its core business to developing next-generation antibody-drug conjugates (ADCs) with novel payloads, following its acquisition of Peak Bio in November 2024.
• The company's lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC, which has shown promising preclinical results in cytotoxicity and immune activation.
• Development of legacy assets, including nomacopan, PAS-nomacopan, and PHP-303, has been suspended, with an impairment loss of $5.18 million recorded for the PHP-303 asset in Q3 2025.
• Akari reported a net loss of $12.0 million for the nine months ended September 30, 2025, and an accumulated deficit of $259.3 million as of that date.
• Cash on hand was approximately $2.5 million as of September 30, 2025, which is projected to fund operations only into the second quarter of 2026, raising substantial doubt about its ability to continue as a going concern.
• The company completed several financing activities, including December 2025 Offerings raising approximately $5 million gross, and an October 2025 Offering raising approximately $2.5 million gross, involving the issuance of ADSs and various warrants.
• A privately negotiated note cancellation and exchange in December 2025 converted approximately $4 million principal amount of 2026 Notes into Pre-Funded Warrants and Note Exchange Warrants.
• Shareholder approval is required for the exercisability of warrants issued in the December 2025 Offerings and Exchange, with a Special Meeting to be called within 75 days of closing.
• Material weaknesses in internal control over financial reporting were identified as of December 31, 2024, related to IT general controls, purchase-to-pay controls, and business combination accounting.
• The company received a Nasdaq notice of non-compliance with the minimum bid price requirement ($0.268 on January 22, 2026, below $1.00) and has until May 25, 2026, to regain compliance.

Sentiment

Score: 2

Explanation: The company is in a precarious financial position with significant recurring losses, an accumulated deficit, and very limited cash runway. The Nasdaq delisting threat and identified material weaknesses in internal controls further compound the negative outlook. While the strategic shift to ADCs and preclinical data are positive, the early stage of development and substantial capital requirements present high risks.

Positives

• Strategic shift to a focused oncology ADC platform with novel payloads (PH1, PH5, PH6) offers potential for differentiated cancer therapies.
• Preclinical data for lead candidate AKTX-101 shows superior cytotoxicity, reduced resistance, better tolerance, and potential synergy with checkpoint inhibitors compared to existing Trop2-targeting ADCs.
• Successful completion of multiple financing rounds in late 2025, including December 2025 Offerings ($5 million gross) and October 2025 Offering ($2.5 million gross), providing some capital infusion.
• Resolution of several legal proceedings, including wrongful termination claims and a breach of contract lawsuit, through settlements.

Negatives

• Significant and recurring net losses, with $12.0 million for the nine months ended September 30, 2025, and an accumulated deficit of $259.3 million.
• Limited cash balance of $2.5 million as of September 30, 2025, which is only sufficient to fund operations into Q2 2026, raising substantial doubt about the company's ability to continue as a going concern.
• Impairment loss of $5.18 million on the PHP-303 intangible asset due to reprioritization and inability to find a collaborative partner.
• Identification of material weaknesses in internal control over financial reporting as of December 31, 2024.
• Nasdaq Capital Market listing is at risk due to non-compliance with the minimum bid price requirement, with a closing price of $0.268 on January 22, 2026.
• Heavy reliance on third parties for preclinical and clinical trials, manufacturing, and potential commercialization, introducing execution risks.
• The ADC platform is based on novel, unproven technologies, making product development timelines and regulatory approval uncertain.

Risks

• History of operating losses and no assurance of future revenues or operating profits.
• Requirement for substantial additional capital to fund operations, with no assurance of availability on acceptable terms, which could lead to delays or termination of product development.
• Material weaknesses in internal control over financial reporting could adversely affect investor confidence and the value of ADSs.
• Failure to initiate clinical studies for active pipeline programs or secure strategic partnerships for legacy assets could delay commercialization for years.
• Prolonged or delayed preclinical studies or clinical trials could prevent timely regulatory approvals.
• Serious adverse events or unexpected properties of product candidates identified during development or after approval could lead to discontinuation or revocation of marketing authorizations.
• Proprietary ADC platform based on novel, unproven technologies may not result in approvable or marketable products.
• Interim or preliminary preclinical/clinical results may change, impacting future development and regulatory decisions.
• Risk of clinical trials being suspended, repeated, or terminated due to non-compliance, negative results, or poor design.
• Misconduct by employees, contractors, or partners, including non-compliance with regulatory standards (e.g., data privacy, anti-kickback laws), could result in significant penalties and reputational harm.
• Highly competitive industry where product candidates may become obsolete or face strong competition from better-funded companies.
• Inability to establish sales, marketing, and distribution capabilities, or secure collaborations, could hinder commercialization.
• Failure of approved product candidates to achieve market acceptance by physicians, patients, or third-party payors.
• Uncertainty of third-party payor coverage and reimbursement status for newly approved products, potentially limiting market access and revenue.
• Additional regulatory burdens and risks associated with commercializing products in foreign markets, including price controls and intellectual property protection challenges.
• Adverse effects from current or future unfavorable economic and market conditions, including geopolitical instability and high inflation.
• Insiders owning a significant amount of outstanding shares could delay or prevent a change in corporate control or entrench management.
• Future sales and issuances of ordinary shares or ADSs could result in additional dilution and cause share price to fall.
• Failure to meet Nasdaq listing requirements could lead to delisting, adversely affecting liquidity and market price.
• The withdrawal of the United Kingdom from the EU (Brexit) could adversely affect business due to diverging regulatory regimes.
• Potential classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to negative tax consequences for U.S. shareholders.
• U.S. investors may face difficulties enforcing civil liabilities against the company or its non-U.S. directors/officers due to English law jurisdiction.

Future Outlook

The company expects to incur significant losses for the foreseeable future as it continues research and development, clinical testing, and regulatory compliance for its ADC product candidates. Future profitability depends on successful development and commercialization, which is expected to take many years, if ever. Substantial additional capital will be required to fund operations, and the company is exploring various financing strategies. The company aims to advance AKTX-101 to a first-in-human trial and progress AKTX-102, while actively seeking strategic partners to license its legacy non-oncology assets.

Management Comments

• We believe these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development.
• Our focus on the development of ADCs that utilize our novel payloads may allow us to develop ADCs with benefits that include more effective cancer-killing properties, activating the immune system, synergizing with other key therapies, greater sustained duration and depth of response, reduced tumor resistance, and improved safety and tolerability.
• We aim to establish AKTX-101 as a best-in-class Trop2-targeting ADC for the treatment of a variety of solid tumors.
• Since the closing of the Merger, we have focused substantially all of our efforts on the development of ADCs and our ADC Platform. As such, we have been actively seeking strategic partners to license these Legacy assets and advance their development externally.
• Our ability to generate revenue sufficient to achieve profitability, if ever, will depend on the successful development and eventual commercialization of our potential therapies, which we expect, if it ever occurs, will take a number of years.
• We believe that PH1 has the potential to generate an immunostimulatory effect and may possess synergies with checkpoint inhibitors, which could improve the longer term control of cancer after the completion of initial treatment.
• We believe this preclinical data suggests that a higher therapeutic index may be possible using AKTX-101 over current Trop2 ADCs available today.
• We believe the absence of observed lung complications, colitis and hypothyroidism in this study may further support AKTX-101s potential suitability and feasibility for use in combination with checkpoint inhibitors, given these side effects are often common with checkpoint inhibitors.

Industry Context

The oncology market, particularly in antibody-drug conjugates (ADCs), is highly competitive and characterized by rapid technological evolution. Current ADC therapies primarily rely on two standard payload classes (microtubule inhibitors or DNA-damaging agents), which have limitations in efficacy, resistance, and toxicity. Akari's strategy to develop ADCs with novel payloads (e.g., spliceosome inhibitors like PH1) represents a differentiated approach aiming to overcome these limitations by offering improved cytotoxicity, immune activation, and safety. This positions Akari as an innovator seeking to disrupt established ADC paradigms, but also exposes it to the risks of unproven technology in a field dominated by larger, better-funded competitors.

Comparison to Industry Standards

• AKTX-101 (PH1 conjugated to a Her2 antibody) demonstrated superior cytotoxic activity in in vitro gastric and breast cancer models compared to Kadcyla, a commercially approved Her2-targeting ADC.
• In an in vivo mouse colon cancer model, Her2-PH1 ADC combined with checkpoint inhibitor therapy (I/O) induced 14 complete tumor regressions (73% of mice) with median survival not reached, compared to 8 CRs (42% of mice) and a median survival of 149 days for Kadcyla + I/O.
• PH1-treated cells contained 765 neoepitope-containing species, approximately 9 times more than DM4 (a standard payload), suggesting PH1's high proficiency in recruiting immune cells.
• PH1 demonstrated less susceptibility to multidrug resistance (MDR) compared to Monomethyl auristatin Es (MMAE), a common ADC payload, indicating a potential advantage in overcoming cancer cell resistance.
• AKTX-101 showed minimal killing of normal human fibroblasts not expressing Trop2 in preclinical in vitro models, suggesting a potentially superior safety profile and higher therapeutic index compared to an approved Trop2-targeting ADC known for bystander effects.
• In a non-human primate (NHP) toxicity study, AKTX-101 was well-tolerated with transient side effects, and notably, no evidence of neutropenia, leukopenia, interstitial lung disease, or mucosal inflammation, which are associated with other Trop2-targeting ADCs using topoisomerase I inhibitors.

Management Changes

Corporate Governance

Legal Proceedings

• Settlement of wrongful termination claims from two former consultants for a total of $0.4 million, payable in monthly installments through November 2025, and continued vesting of restricted stock units.
• Settlement of a breach of contract lawsuit filed by Sabby Volatility Warrant Master Fund Ltd. by issuing 272,450 ADSs to Sabby on June 13, 2025.
• Settlement of a claim from a former employee seeking unpaid wages and penalties for approximately $16,588 in September 2024.
• Settlement with the Palo Alto landlord for a default judgment of $796,773, agreeing to pay $175,000 cash and issue a secured promissory note for $325,000 in September 2024.

Related Party Transactions

• December 2025 Offerings: Certain directors and officers participated in a concurrent private placement, receiving 2,563,713 Pre-Funded Warrants and Series G Warrants.
• August 2025 Note Offering: Company directors participated, purchasing August 2025 Notes with an aggregate purchase price of $1,511,000 and principal amount of $1,888,750. Dr. Hoyoung Huh's purchase included cancellation of $837,433 in outstanding principal and accrued interest from his January 2024 Note.
• March 2025 Private Placement: Company directors, including Dr. Hoyoung Huh and Dr. Samir R. Patel, participated. Dr. Huh's purchase of $1 million of Units was satisfied by cancelling $1.0 million of notes previously issued to him.
• May 2024 Convertible Notes: Issued to Dr. Ray Prudo and Dr. Samir Patel for an aggregate of $1.0 million. They later converted $125,000 each of principal and accrued interest into ADSs.
• Dr. Huh Notes: Assumed $0.9 million in 2021 Notes and a $0.75 million January 2024 Note from Peak Bio acquisition. Portions of these notes were cancelled/exchanged in March and August 2025 financings.
• The Doctors Laboratory (TDL): Leased office space and received administrative services from TDL, an entity with a common director (Dr. Ray Prudo). Incurred expenses of less than $0.1 million plus VAT in 2025 and 2024.
• An amount due to an entity where Dr. Hoyoung Huh is a director was assumed in November 2024, totaling less than $0.1 million as of September 30, 2025.

Stakeholder Impact

• Shareholders: Face significant dilution risk from ongoing and future equity financings and warrant exercises. The Nasdaq delisting threat could severely impact liquidity and share price. The company's going concern doubt poses a fundamental risk to investment value.
• Employees: Subject to workforce reductions (e.g., May 2024 RIF of 67% of workforce) due to program reprioritization, impacting job security and morale. New management appointments and compensation structures are in place.
• Customers (potential): The strategic shift to ADCs and preclinical data for AKTX-101 offer hope for novel, more effective cancer therapies, potentially providing new treatment options for various solid tumors.
• Creditors: The company's substantial losses, accumulated deficit, and going concern doubt increase credit risk. Debt obligations, including convertible notes and promissory notes, are significant, though some have been settled or exchanged.
• Regulatory Authorities: The company is subject to ongoing scrutiny regarding internal controls, clinical trial conduct, and compliance with listing requirements (Nasdaq). Failure to meet these could result in sanctions or delisting.

Next Steps

• Obtain shareholder approval for the issuance of Ordinary Shares underlying the Warrants from the December 2025 Offerings and Exchange at a Special Meeting within 75 days of closing, or subsequent meetings every 40 days until approval is obtained.
• Continue to seek substantial additional capital through debt or equity financings, credit facilities, or out-licensing arrangements to fund operations beyond Q2 2026.
• Remediate identified material weaknesses in internal control over financial reporting.
• Regain compliance with Nasdaq's minimum bid price requirement ($1.00 per ADS) by May 25, 2026, to avoid delisting.
• Advance AKTX-101 to potential initiation of a first-in-human (FIH) trial, including defining tumor strategy, developing additional preclinical data, securing manufacturing supply, and completing formal non-clinical and toxicology studies.
• Progress AKTX-102 through additional efficacy and safety preclinical experiments.
• Actively seek strategic partners to license legacy non-oncology assets (nomacopan, PAS-nomacopan, PHP-303) to generate capital and advance their development externally.
• File a registration statement for the resale of ADSs issuable upon exercise of October 2025 Warrants and Placement Agent Warrants within 30 days of the October 2025 Closing Date.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by recurring substantial net losses, a massive accumulated deficit, and a critically low cash balance that only sustains operations for a few more months. The 'going concern' warning from auditors is a red flag. Furthermore, the Nasdaq delisting notice due to a sub-$1.00 share price indicates significant market erosion and investor lack of confidence. While the strategic pivot to ADCs and promising preclinical data are noted, the early stage of development for these programs means commercialization and profitability are years away, if ever. The identified material weaknesses in internal controls suggest fundamental operational issues. The extensive reliance on dilutive financing rounds and related-party transactions further complicates the investment thesis. Given the high financial risk, regulatory non-compliance, and uncertain path to profitability, a seasoned investor would likely recommend a strong sell.

Keywords

Akari Therapeutics, ADC, Antibody-Drug Conjugates, Oncology, Cancer Therapy, PH1 Payload, AKTX-101, Trop2-targeting ADC, Biotechnology, SEC Filing, S-1 Registration, Nasdaq, Going Concern, Clinical Development, Preclinical Studies, Drug Discovery, Biopharmaceutical, Warrants, Private Placement, Capital Raise, Intellectual Property, Corporate Governance, Financial Reporting, Risk Factors